Kymera Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
B.Riley reiterated a Buy rating and $155 price target for Kymera Therapeutics (KYMR) after new trial data. The stock is up 104% year-over-year. Analysts note potential for re-rating if BROADEN2 trial shows positive results. Multiple analysts have raised price targets, citing the Phase 2b study as a key catalyst.
Goldman Sachs resumed coverage on Kymera Therapeutics (KYMR) with an Early-Stage Biotech rating. The stock has surged 120% over the past year to $115.47, trading near its 52-week high of $130.05. Analysts have set price targets ranging from $125 to $170, citing ongoing clinical trials and financial status as key factors.
Kymera Therapeutics (KYMR) presented its focus on oral immunology at Citigroup's Biopharma Summit, highlighting STAT6 and IRF5 programs. STAT6 aims to treat type 2 inflammation, with Phase III readout expected by year-end 2024. IRF5 targets autoimmune diseases, with human genetics and biological validation. The company seeks to become an independent commercial entity, focusing on immunology. Kymera's stock is up 2.54% to $118.36.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning KYMR (Kymera Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent KYMR coverage spans technology, financial news and earnings.
In the last 30 days, KYMR insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($744K). The most active reporter was Adams Brian, Chief Legal Officer, with 3 filings.
Positive early‑stage data on the STAT6 degrader could lift the stock as investors price in a potential Phase 2b catalyst.
Analyst upgrades may support short-term price appreciation.
Positive early safety data and accelerated enrollment suggest near‑term upside potential if trials meet endpoints.
Insider sale may signal lack of confidence, could pressure stock.
Analyst rating and target change may influence short‑term price action.
AlphAI scores every news story that mentions KYMR with an AI model for sentiment and relevance, and aggregates insider trades from Kymera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
B.Riley reiterated a Buy rating and $155 price target for Kymera Therapeutics (KYMR) after new trial data. The stock is up 104% year-over-year. Analysts note potential for re-rating if BROADEN2 trial shows positive results. Multiple analysts have raised price targets, citing the Phase 2b study as a key catalyst.
2 min readGoldman Sachs resumed coverage on Kymera Therapeutics (KYMR) with an Early-Stage Biotech rating. The stock has surged 120% over the past year to $115.47, trading near its 52-week high of $130.05. Analysts have set price targets ranging from $125 to $170, citing ongoing clinical trials and financial status as key factors.
2 min readKymera Therapeutics (KYMR) presented its focus on oral immunology at Citigroup's Biopharma Summit, highlighting STAT6 and IRF5 programs. STAT6 aims to treat type 2 inflammation, with Phase III readout expected by year-end 2024. IRF5 targets autoimmune diseases, with human genetics and biological validation. The company seeks to become an independent commercial entity, focusing on immunology. Kymera's stock is up 2.54% to $118.36.
2 min readAdams Brian (Chief Legal Officer) sold 6,371 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $116.83 ($115.55–$117.57, $0.74M total) across 3 trades on 2026-09-04.
1 min readRBC Capital's Brian Abrahams maintained a Hold rating on Kymera Therapeutics (KYMR) with a $112 price target, while LifeSci Capital's Patrick Dolezal initiated coverage on vTv Therapeutics (VTVT) with a Buy rating and $60 target. KYMR's consensus price target is $135.22, and VTVT's is $58.50.
2 min readKymera Therapeutics (KYMR) announced presentations on KT-621, its oral STAT6 degrader, at ERS and EADV congresses. The company completed enrollment in the BROADEN2 Phase 2b trial for atopic dermatitis, with topline data expected by year-end 2026. Phase 3 trials are planned for mid-2027. The BREADTH Phase 2b asthma trial is ongoing, with data expected in late 2027.
2 min readKymera Therapeutics (KYMR) reported Q2 2026 collaboration revenue of $65M, including a $45M Gilead option fee and $20M Sanofi milestone. Cash and investments were $1.5B as of June 30, 2026, runway into 2029. R&D rose to $119.5M. KT-621 AD Phase 3 initiation is mid-2027, and asthma data is late 2027.
7 min readKymera Therapeutics (NASDAQ: KYMR) reported Q2 2026 results and updated its pipeline. Enrollment in KT-621 BROADEN2 Phase 2b atopic dermatitis finished nearly six months early, shifting topline data to year-end 2026 and Phase 3 start to mid-2027. KT-621 asthma data is due late 2027. KT-579 Phase 1 data is expected 4Q26. Cash was $1.5B as of June 30, 2026.
6 min readKymera Therapeutics (KYMR) shares rose about 1% to $105.48 after Q2 results. The company reported collaboration revenue of $65.0m versus $11.5m a year earlier, with net loss of $61.2m (vs $76.6m) and trailing 12-month net loss of $299.6m. Management said no further 2026 collaboration revenue is expected without new milestones.
6 min readKymera Therapeutics said its Phase 2b BROADEN2 trial of KT-621, an oral STAT6 degrader for atopic dermatitis, closed enrollment about six months early, moving topline results from mid-2027 to year-end 2026 and compressing Phase 3 start to mid-2027. The company cited Phase 1 data showing up to 98% STAT6 degradation in peripheral blood.
5 min read
